The National Medical Products Administration (NMPA) has approved Bayer’s (ETR: BAYN) Category 1 drug Kerendia (finerenone) for adult patients with chronic kidney disease (CKD) associated with type 2 diabetes. This approval marks a significant advancement in the treatment of diabetic kidney disease, offering a new option to slow disease progression and reduce the risk of end-stage renal disease.
Drug Mechanism
Finerenone is a nonsteroidal, selective mineralocorticoid receptor (MR) antagonist. By targeting MR hyperactivation in the kidney, heart, and blood vessels, the drug reduces inflammation and fibrosis, addressing key pathways involved in CKD progression.-Fineline Info & Tech
